As enclosed herewith.

Nukleus Office Solutions Limited CIN NO -L70101DL2019PLC355618 │PH: +91-9667049487│ Email: cs@nukleus.work│ Website: www.nukleus.work│ Date: November 05, 2026 The Manager, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code: 544370 Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Receipt of In-principle approval from BSE Limited for issue and allotment of up to 2,01,600 Equity Shares under the "Nukleus Employees Stock Option Scheme - I" (ESOS - I). Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we inform the Exchange that BSE Limited, vide letter no. DCS/ESOP/IP/RD/318/2026-27 dated November 03, 2026 (copy enclosed), has granted in-principle approval for issue and allotment of up to 2,01,600 Equity Shares of ₹10/- each to the permanent employees of the Company on exercise of options under the Nukleus Employees Stock Option Scheme - I ("ESOS - I"), subject to the conditions stated in the letter. The Company has proposed ESOS - I to: 1. attract, reward, motivate and retain employees, and encourage high individual performance; 2. give employees a sense of ownership and align their interests with those of the shareholders; 3. retain talent over the long term, as options vest only after at least one year and subject to continued employment; and 4. support the Company's growth and expansion plans through a stable and motivated team, without any cash outlay, as the Scheme is equity-settled by fresh allotment. The Company will comply with the conditions of the in-principle approval, including notifying the Exchange under Regulation 10(c) of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021 after allotment of shares. This is for your information and records. Thanking You, For Nukleus Office Solutions Limited Vinay Rathore Membership No. 75848 (Company Secretary & Compliance Officer) Encl.: Copy of BSE in-principle approval letter dated November 03, 2026 Regd. Office: 1102, Barakhamba Tower, 22 Barakhamba Road, Connaught Place, New Delhi, Central Delhi- 110001, Delhi Corporate Office: Plot No 29, Sector -142, Noida, UP – 201305